Selected article for: "MD molecular dynamic simulation and molecular dynamic"
Author: Rana, Meenakshi; Pooja,; Chowdhury, Papia
Title: Ivermectin and Doxycycline Combination as a Promising Drug Candidate Against SARS-CoV-2 Infection: A Computational Study
  • Cord-id: iyh1ewvc
  • Document date: 2020_11_8
    • ID: iyh1ewvc
    Snippet: In the present study, we have described how by using molecular docking and molecular dynamic (MD) simulation studies the combination drug of ivermectin and doxycycline can be used as a potential inhibitor for SARS-CoV-2 virus. In lieu of unavailability of specific cure of COVID-19 till now various possibilities for individual and combination drugs have been explored by the medical practitioners/scientists for the remedial purpose of CoV-2 infections. $3CL^{pro}$ is the main protease of SARS-CoV-
    Document: In the present study, we have described how by using molecular docking and molecular dynamic (MD) simulation studies the combination drug of ivermectin and doxycycline can be used as a potential inhibitor for SARS-CoV-2 virus. In lieu of unavailability of specific cure of COVID-19 till now various possibilities for individual and combination drugs have been explored by the medical practitioners/scientists for the remedial purpose of CoV-2 infections. $3CL^{pro}$ is the main protease of SARS-CoV-2 virus which plays an essential role in mediating viral replication in the human body. $3CL^{pro}$ protein can serve as an attractive drug target. In this work, we have studied drug: $3CL^{pro}$ interactions by in silico molecular docking and MD simulation approaches. Common and easily available antiviral drugs ivermectin, doxycycline and their combination have been proved their valid candidature to be used as potential drug candidates against SARS-CoV-2 infections.

    Search related documents:
    Co phrase search for related documents
    • accessible surface area and acute respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • accurate efficient and active ingredient: 1
    • accurate efficient and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • accurate efficient and acute respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • active ingredient and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • active ingredient and acute respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • active ingredient and liver disease: 1, 2
    • active patient and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • active patient and acute respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • active patient and liver disease: 1, 2
    • active patient number and acute respiratory: 1
    • active patient number and acute respiratory syndrome coronavirus: 1
    • acute respiratory and adme analysis: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute respiratory and liver disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory and lopinavir oseltamivir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute respiratory and lopinavir ribavirin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory and low binding affinity: 1, 2, 3, 4, 5, 6, 7
    • acute respiratory and low inhibition: 1, 2, 3, 4
    • acute respiratory syndrome coronavirus and low inhibition: 1, 2, 3, 4